辉瑞Ibrance在治疗阑尾癌方面显示出希望：研究

2024-10-17 06:18

Pfizer’s (NYSE:PFE) breast cancer drug Ibrance, also known as palbociclib, showed encouraging results in the treatment of a certain type of appendix cancer, according to a new study.
The study showed that palbociclib was able to stabilize tumor growth and reduced blood tumor marker levels in patients with peritoneal mucinous carcinomatosis. The cancer, which is rare, is often resistant to standard chemotherapy.
The study was published in the Oct. 16 online edition of the Journal of Clinical Oncology.
Researchers said the study also showed Ibrance was able to slow or stop the multiplication of cancer cells. They added that the next step was to test the drug with chemotherapies and targeted drug therapies to see if its effectiveness could be enhanced, according to a statement.

More on Pfizer